Save time and jump to the most important pieces.
Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
11/22/2024 | $14.00 | Equal Weight | Wells Fargo | |
10/11/2024 | $70.00 | Equal-Weight | Morgan Stanley | |
10/1/2024 | $15.00 | Positive → Neutral | Susquehanna | |
9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies | |
8/19/2024 | $3.00 | Buy | H.C. Wainwright | |
7/31/2024 | Neutral → Outperform | Daiwa Securities | ||
7/29/2024 | Underperform → Peer Perform | Wolfe Research | ||
7/25/2024 | $100.00 → $70.00 | Buy → Hold | TD Cowen |
4 - MAXLINEAR, INC (0001288469) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - MAXLINEAR, INC (0001288469) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
8-K - Predictive Oncology Inc. (0001446159) (Filer)
10-Q - Predictive Oncology Inc. (0001446159) (Filer)
EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of biopharmaceutical finance veteran Mr. Andrew Einhorn to its Business Advisory Board. "Andrew Einhorn brings a wealth of senior financial leadership experience in the biopharmaceutical industry to our Business Advisory Board, and I am very pleas
EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of Dr. Bernard A. Harris, Jr. to its newly-formed Business Advisory Board (BAB). "I am very pleased to welcome Dr. Harris to our new Business Advisory Board," said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. "As we continue
EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced the appointment of healthcare commercial and business development veteran Veena Rao, Ph.D., MBA, to its Board of Directors. Dr. Rao currently serves as Chief Business Officer of Portal Instruments, where she leads the identification, evaluation, and negotiation of
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 40,064.06 while the NASDAQ fell 1.25% to 17,124.88. The S&P 500 also fell, dropping, 0.38% to 5,406.26. Check This Out: Jim Cramer: This Tech Stock Is ‘Absolutely Terrific,’ But Jumia? It’s Not Making A Lot Of Money Leading and Lagging SectorsReal estate shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 2.5%. Top Headline Honeywell International Inc. (NASDAQ:HON) reported second-quarter results and lowered FY24 EPS guidance. Adjusted EPS was $2.49 (+8% Y/Y), beat
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $70.
MaxLinear, Inc. (NASDAQ:MXL), a leading provider of RF, analog, digital and mixed-signal integrated circuits, today announced that it will participate in the following upcoming financial conferences: 13th Annual Roth Technology Conference in New York on Nov. 20th Wells Fargo 8th Annual TMT Summit in Rancho Palos Verdes, CA on Dec. 3rd. MaxLinear's presentation is scheduled for 12:45 p.m. PT. A webcast of the session will be available at https://investors.maxlinear.com. UBS Global Technology and AI Conference in Scottsdale, AZ on Dec. 4th. MaxLinear's presentation is scheduled for 8:55 a.m. MT. A webcast of the session will be available at https://investors.maxlinear.com. Northla
MaxLinear, Inc. (NASDAQ:MXL)("MaxLinear"), a leading provider of RF, analog, digital and mixed-signal integrated circuits, today announced that it has granted equity awards ("the Inducement Grants") under its 2024 Inducement Equity Incentive Plan to newly hired employees. The Inducement Grants were previously approved by the Compensation Committee of the Board of Directors of MaxLinear. Information regarding the equity awards can be found on MaxLinear's investor relations website at: https://investors.maxlinear.com/ About MaxLinear, Inc. MaxLinear, Inc. (NASDAQ:MXL) is a leading provider of radio frequency (RF), analog, digital and mixed-signal integrated circuits for access and conne
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
PITTSBURGH, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ:POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended September 30, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $345,686 for the quarter. Predictive Oncology also announced today that the company's Board of Directors, working with a strategic advisor, has i
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enrollment in CLASP IITR trial for PASCAL tricuspid First implants in the JOURNEY pivotal trial with the Edwards J-Valve AR system Rei
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with
Wells Fargo initiated coverage of MaxLinear with a rating of Equal Weight and set a new price target of $14.00
Morgan Stanley resumed coverage of Edwards Lifesciences with a rating of Equal-Weight and set a new price target of $70.00
Susquehanna downgraded MaxLinear from Positive to Neutral and set a new price target of $15.00
SC 13G - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - MAXLINEAR, INC (0001288469) (Subject)
SC 13G/A - MAXLINEAR, INC (0001288469) (Subject)